MorphoSys bags €446m licensing deal with GSK for RA candidate
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has licensed German company MorphoSys' most advanced unpartnered product candidate, MOR103, for €22.5m up front and potential milestone payments of up to €423m. MOR103 is a HuCAL?derived antibody against GM?CSF (granulocyte-macrophage colony-stimulating factor), which has concluded Phase I/II development in mild-to-moderate rheumatoid arthritis.